Company Filing History:
4 out of 3,222 
2 out of 4,945 
2 out of 168 
Years Active: 2011-2016
Title: Paul Goldsmith: Innovator in PI3K Inhibitor Compounds
Introduction
Paul Goldsmith is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of PI3K inhibitor compounds. With a total of 4 patents to his name, Goldsmith's work has the potential to impact the treatment of various disorders, including cancer.
Latest Patents
Goldsmith's latest patents focus on benzopyran and benzoxepin PI3K inhibitor compounds and their methods of use. These compounds, represented by Formulas I and II, include stereoisomers, geometric isomers, tautomers, solvates, metabolites, and pharmaceutically acceptable salts. They are designed to inhibit lipid kinases, including p110 alpha and other isoforms of PI3K. The methods disclosed in his patents are aimed at the diagnosis, prevention, or treatment of disorders mediated by lipid kinases in mammalian cells.
Career Highlights
Throughout his career, Paul Goldsmith has worked with prominent companies in the pharmaceutical industry, including Genentech, Inc. and Hoffmann-La Roche Inc. His experience in these organizations has contributed to his expertise in developing innovative compounds that address critical health issues.
Collaborations
Goldsmith has collaborated with notable individuals in his field, including Steven Huy Do and Richard A. Goldsmith. These partnerships have likely enhanced his research and development efforts, leading to the successful creation of his patented compounds.
Conclusion
Paul Goldsmith's contributions to the field of PI3K inhibitors demonstrate his commitment to advancing medical science. His innovative work has the potential to provide new treatment options for serious health conditions, particularly cancer.